Evidence map›Paper›PMID 37013108›Full record

ArticleCase reports in oncology

Pembrolizumab Induced Sclerosing Cholangitis: Why You Need a Liver Biopsy.

Ian Liang, Geoffrey Chu, Robert Zielinski

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Clinical features, treatment, and outcome of pembrolizumab induced cholangitis.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Ian LiangDepartment of Medicine and Oncology, Orange Health Service, Orange, NSW, Australia.
Geoffrey ChuDepartment of Medicine and Oncology, Orange Health Service, Orange, NSW, Australia.
Robert ZielinskiDepartment of Medicine and Oncology, Orange Health Service, Orange, NSW, Australia.
Western NSW Local Health District · AUThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The advent of checkpoint inhibitor immunotherapy has rapidly changed the landscape of the management of cancers. However, its use has also been associated with the rise of immunotherapy-related adverse effects (irAEs). There has been an emergence in recent years of sclerosing cholangitis as a mimic of the classical autoimmune hepatitis irAE. We present a case of a 59-year-old female who received pembrolizumab for stage IV lung adenocarcinoma and developed an immune checkpoint inhibitor (ICI) related sclerosing cholangitis diagnosed on radiological and histopathological grounds. This patient was successfully treated with prednisone, azathioprine, and ursodeoxycholic acid. Clinicians should be aware that ICI sclerosing cholangitis is a rare hepatic complication of ICIs. The workup for ICI-associated mixed liver function test derangement that is steroid resistant should include a magnetic resonance cholangiopancreatography to investigate for changes of sclerosing cholangitis and a liver biopsy if the magnetic resonance cholangiopancreatography is nondiagnostic.

Indexed as

Immune checkpoint inhibitorImmunotherapy-related adverse effectsLung cancerPembrolizumabSclerosing cholangitis

Identifiers

PMID37013108
PMCPMC10066501
OpenAlexW4362472680

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.